论文部分内容阅读
目的分析131I联合唑来膦酸治疗甲状腺癌骨转移的临床疗效。方法采用回顾性队列研究,将2006-2011年在某医院住院治疗的150例患者分为治疗组和对照组,治疗组应用131I联合唑来膦酸治疗,对照组单纯给以131I治疗,两组对象均随访观察6个月。根据治疗后疼痛缓解和生活质量改善判断疗效。结果治疗组总有效率为91.25%(73/80),对照组总有效率为78.58%(55/70),两组治疗结果差异有统计学意义(P<0.05);治疗组生活质量改善总有效率为90%(72/80),对照组总有效率为77.14%(54/70),两组生活质量改善总有效率差异有统计学意义(P<0.05)。主要不良反应为白细胞和血小板Ⅰ~Ⅱ度下降,少数患者出现一过性骨痛加重,出现轻微恶心呕吐,两组主要不良反应的差异不明显。结论 131I联合唑来膦酸治疗甲状腺癌骨转移是一种综合有效的治疗方法,比单用131I治疗甲状腺癌骨转移的效果更好,能够更有效地改善患者的生存质量。
Objective To analyze the clinical efficacy of 131I combined with zoledronic acid in the treatment of bone metastases from thyroid cancer. Methods A retrospective cohort study was conducted to divide 150 hospitalized patients in a hospital from 2006 to 2011 into treatment group and control group. The treatment group was treated with 131I combined with zoledronic acid and the control group with 131I alone. The two groups Subjects were followed up for 6 months. According to the treatment of pain relief and improve the quality of life to determine the efficacy. Results The total effective rate was 91.25% (73/80) in the treatment group and 78.58% (55/70) in the control group, with significant difference between the two groups (P <0.05). The total quality of life in the treatment group was significantly improved The effective rate was 90% (72/80). The total effective rate in the control group was 77.14% (54/70). There was significant difference between the two groups in the total effective rate (P <0.05). The main adverse reactions were leukopenia and platelet Ⅰ ~ Ⅱ decreased, a few patients had a transient increase in bone pain, mild nausea and vomiting, the two groups had no significant difference in adverse reactions. Conclusion 131I combined with zoledronic acid in the treatment of bone metastases of thyroid cancer is a comprehensive and effective treatment, which is more effective than 131I in the treatment of bone metastases of thyroid cancer, and can effectively improve the quality of life of patients.